News & Updates
Filter by Specialty:
MMP7 predicts progression, death in antifibrotic-treated IPF
Higher levels of matrix metalloprotease 7 (MMP7) pretreatment are predictive of 12-month progression and mortality among patients with idiopathic pulmonary fibrosis (IPF) who have been treated with antifibrotics, reveals a recent study.
MMP7 predicts progression, death in antifibrotic-treated IPF
28 Jun 2025
Tocilizumab with or without MTX for acute RA: Does combo work better than mono?
Subcutaneous tocilizumab, used either as a monotherapy or in combination with methotrexate (MTX), shows greater efficacy than MTX alone in Chinese patients with active rheumatoid arthritis (RA) who have not adequately responded to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Tocilizumab with or without MTX for acute RA: Does combo work better than mono?
27 Jun 2025
MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis
Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.
